Replies to post #5537 on Synaptogenix Inc (SNPX)

[SF Wolf]

In a conversation I had with Dr. Alkon last year he told me that they were looking for a SIB improvement of 3 or better in the Completers Group. They doubled that with the non-memantine patients!

"At week 15, non-memantine patients in the Completers Group treated with 20µg (n=14) showed an SIB improvement of 6.24, while the placebo patients (n=11) showed a decline in their SIB scores of -0.12 for an overall treatment ? of 6.36 from baseline (p=0.0488)."

[runncoach]

I see the twitter hot shots are claiming a "subset of a subset" type of thing. Well I think when research already exists that memantine type drugs interfere with the PKCe pathway and you can clearly differentiate between patients on that type of drug and those who are NOT on that type of drug and can show such huge differences in test score improvement... well that's not exactly playing around with data hoping to stumble onto something.

There have been so many doubts posted here over the last year but every time we get additional data whether it was from the original dosing study that did show immediate efficacy to the compassionate use patients highly detailed numbers, to the 20 ug dose being the best measurement, to the continued improvement weeks after last dosing, to now this non-memantine population...its all played out like those that follow the science have said it would. This is no longer success in mice or in labs. It is showing efficacy in humans from what we're seeing. Now we have Dr Perry excited and on board and finally have a confirmatory study in the works. All very exciting.